AI-generated · cited to primary sources · not investment advice
Alkem Lab (539523) Aug 2025 Filing Analysis
Does management do what it says?
U.S. sales grew by 28% Y-o-Y in Q2 FY26, far outperforming the mid-single-digit guidance, leading management to upgrade expectations to double-digit growth for the full year. (1 exceeded across 1 tracked commitment)
“So overall, I think our guidance was about mid-single-digit kind of growth from U.S. markets. I will maintain at least that growth.”
Targeting 25,000 Jan Aushadhi Kendras by March 2027. — target: 25,000 Kendras
“With 17,990 Jan Aushadhi Kendras operational targeting 25,000 by March 2027”
See the full cited Management analysis of Alkem Lab
How durable is the business?
Alkem continues to outperform the market in chronic and sub-chronic segments like Anti-Diabetics (1.4x market growth) and Neuro/CNS (1.2x market growth). (5 expanding)
“We have outperformed the IPM across seven key therapies, namely GI... Anti-Diabetics at 1.4x, Neuro/CNS at 1.2x and Respiratory, 1.4x of the market.”
See the full cited Business Model analysis of Alkem Lab
What could break the thesis?
The risk is stable; NLEM products constitute approximately 30% of the portfolio, with WPI-linked price increases limited to 1.8%. (2 stable, 1 emerging)
“our NLEM percentage, the portfolio that we have is around 30%. And there is volume growth. Price growth is just one piece.”
EASING. The company reported an improved gross margin of 65.3% in Q1FY26 compared to 64.5% in Q1FY25 and 59.3% in Q4FY25, indicating that cost pressures on raw materials are being managed or are subsiding. (4 easing)
“Our performance was driven by strong topline growth and an improved gross margin, which resulted in a better EBITDA profile.”
See the full cited Risk analysis of Alkem Lab
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.